Heart Failure PHARM Flashcards
Quadruple therapy
- ARNI
- angiotensin receptor / neprilysin inhibitor
Ex. valsartan/sacubitril - beta blocker
- OLOL - SGLT2 inhibitor
SOdium glucose transporter 2 inhibitor
Ex. GLIFLOZIN - MRA
mineralcorticoid receptor antagonist
Ex. spironolactone
ARNI
Example
Angiotensin receptor neprilysin inhibitor
- valsartan with 2. sacubitril
ARNI
MOA
Angiotensin receptor blocker
- Valsartan
- blocks angiotensin II receptors
- Prevens 1. vasoconstriction (vasodilation)
2. prevents release of aldosterone (prevents reuptake sodium, water)
- prevents activation SNS
- prevents remodelling
Sacubitril
- neprilysin inhibitor
- Neprylysin cleaves natriuretic peptides (diuresis, sodium loss), bradykinin (vasodilation, vascular permeability), angiotensin I and II (vasoconstriction, aldosterone release, sodium and water reabsorption)
NET EFFECT
1. block RAAS (vasodilation, decrease SNS activation, remodelling, decrease sodium and water reabsorption)
2. increase bradykinin and natriuretic peptides (increase fluid and sodium loss, increase vasodilation)
Benefits
ARNI
- decrease all cause mortality
- decrease VS mortality
- decrease hospitalizations HF
- decrease HF symptoms
- nephroprotective
benefit > ACEi and ARB alone
Rules for prescribing
ARNIs
washout 36 hours if ACEi D/C
can start right away if on ARB
start low go slow, work up
blood work 1 week after start, increase dose
Can increase dose every 2-4 weeks
Blood work monitoring
ARNI
- electrolytes (sodium, potassium)
- creatinine (kidney function)
- GFR (> 30mL/min)
- Blood pressure (> 100mmHg)
SE ARNI
- ARB SE
- Hyperkalemia
- Hypotension
- cough and angioedema (cross reactivity with ACEi 8%)
- teratogenic - neprilysin inhibitors SE
- build up bradykinin (cough, angioedema)
Contraindications
ARNI
- angioedema
- ACEi (cannot prescribe within 36 hours)
- Hypotension < 100mmHg
- GFR < 30ml/min
- loss of the RAAS to maintain afferent arteriole GFR results in kidney failure?
- do not clear the drug (dangerous)
Angiotensin Converting Enzyme Inhibitors
Indications HF
Post MI with HTN and HF
HFrEF < / = 40% (who do not tolerate ARNI)
ACE inhibitor
MOA
- block ACE prevent formation angiotensin II
- prevents vasoconstriction, lowering afterload
- prevents aldosterone, and sodium and water retention, decreasing preload
- prevents SNS activation, lowering afterload and preload (vasoconstriction arteries, veins)
- prevents breakdown of bradykinin (vasodilation)
INCREASES STROKE VOLUME OF THE HEART IN HEART FAILURE
ACE inhibhitor
SE
- first dose hypotension
- hypotension
- hyperkalemia
- neutropenia
- teratogenic
- kidney failure (contraindicated bilateral renal stenosis)
- cough and angioedema (10/100)
ACE inhibitor
Examples
RamIPRIL
PerindoPRIL
reduce all cause moratlity
reduce CV death
reduce hospitalization
reduce HF symptoms
ARNI more effective than ACEi
Rules for prescribing
ACEi
- start low go slow
- titrate every 1-2 weeks
- repeat blood work
- potassium
- creatinine (kidney function)
- GFR
- BP - monitor for symptomatic hypotension (likely in HF, low CO = low BP)
- stop and reduce dose if BP < 90mmHg - Low potassium diet
Contraindications
ACEi
potassium supplements, salts (hyperkalemia)
hypotension (lower dose if < 90mmHg)
pregnancy
angioedema
D/C potassium sparing diruetics for 2-3 days before starting (to prevent hyperkalemia)
Angiotensin Receptor Blockers (ARBs)
Examples
ValSARTAN
CandeSARTAN